...
首页> 外文期刊>Medicine. >The efficacy of Chinese herbal medicine as an adjunctive therapy for colorectal cancer: A protocol for systematic review of randomized controlled trials
【24h】

The efficacy of Chinese herbal medicine as an adjunctive therapy for colorectal cancer: A protocol for systematic review of randomized controlled trials

机译:中草药作为结直肠癌的辅助治疗的疗效:一种随机对照试验的系统综述议定书

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: Colorectal cancer (CRC) is a public health problem and the world's leading cancer killer. It is a disease with high incidence and mortality. Although chemotherapy has achieved some success in the treatment of CRC, drug resistance and tumor metastasis caused by chemotherapy are still the main causes of death in patients with CRC. Notably, many side effects associated with chemotherapy, such as nausea, vomiting, and peripheral neurotoxicity, are major challenges in the treatment of patients with CRC. Chinese herbal medicine (CHM) has been widely used as an adjunctive therapy for CRC, but its efficacy and safety are still uncertain. The aim of this systematic review is to assess the efficacy and safety of CHM for the treatment of CRC. Methods: A comprehensive retrieval will be performed in the following electronic databases: PubMed, Cochrane Library, EMBASE, Web of Science, CNKI, SinoMed, VIP, and Wan Fang Data. The methodologic quality of randomized controlled trials will be assessed using the Cochrane risk assessment tool. Review Manager 5.3 software will be used for data synthesis and analysis. Funnel plot analysis and Egger test will be used to assess publication bias. The Grading of Recommendations Assessment, Development and Evaluation standard will be used to generate summary of finding table. Results: The results of this systematic review will be used to summarize and evaluate the evidence from randomized controlled clinical trials of CHM as adjuvant therapy for CRC. Conclusion: This review will provide a detailed summary of the evidence to assess the efficacy and safety of CHM for CRC.
机译:背景:结肠直肠癌(CRC)是一个公共卫生问题和世界领先的癌症杀手。它是一种高发病率和死亡率的疾病。虽然化疗在治疗CRC的治疗方面取得了一些成功,但由化疗引起的耐药性和肿瘤转移仍然是CRC患者死亡的主要原因。值得注意的是,与化疗相关的许多副作用,例如恶心,呕吐和周围神经毒性,是治疗CRC患者的主要挑战。中草药(CHM)已被广泛用作CRC的辅助治疗,但其疗效和安全性仍然不确定。该系统审查的目的是评估CHM治疗CRC的疗效和安全性。方法:将在以下电子数据库中进行全面检索:PubMed,Cochrane库,Embase,Science,CNKI,SINOMED,VIP和WAN FANG数据。随机对照试验的方法质量将使用Cochrane风险评估工具进行评估。查看Manager 5.3软件将用于数据综合和分析。漏斗情节分析和Egger测试将用于评估出版物偏差。建议评估,发展和评估标准的评分将用于生成查找表的摘要。结果:该系统审查的结果将用于总结和评估来自CHM随机对照临床试验的证据作为CRC的辅助治疗。结论:本综述将提供详细的证据摘要,以评估CRC CHM的疗效和安全性。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号